Overweight

Recent data suggest that mangos could help improve certain risk factors for chronic disease in patients who are overweight or obese, according to researchers.

Patients with cancer and overweight or obesity had better outcomes with immune checkpoint inhibitors than lighter patients, but only when they received weight-based dosing of the therapy, study results showed.

Risks for severe COVID-19 complications start to rise among adults with a BMI of at least 23 kg/m², with effects greatest among those younger than 40 years, according to data published in The Lancet Diabetes & Endocrinology.

Children with a high genetic risk for developing type 1 diabetes are at an increased risk for the disease if they have overweight or obesity from age 2 to 10 years, according to trial data published in Diabetologia.

The Endocrine Society recently held its annual meeting. Highlights from the virtual conference were among the top stories in endocrinology last week.

Adults with obesity who continued once-weekly semaglutide therapy beyond 20 weeks saw continued weight loss or weight maintenance compared with adults who were switched to placebo, data from the STEP 4 study show.

Weight gain from early adulthood to midlife, as well as consistent obesity throughout adulthood, were associated with an increased risk for gout, according to data published in Arthritis Research & Therapy.

Children who were overweight and had low-level prenatal lead exposure may have worsened kidney function later in life, according to research published in Environment International.

Metabolic dysfunction-associated fatty liver disease is highly prevalent among overweight and obese adults, according to Clinical Gastroenterology and Hepatology.

Adults with obesity assigned the GLP-1 receptor agonist semaglutide experienced substantial weight loss compared with placebo, with more than half of participants losing 15% of body weight, according to data from the STEP 1 study.